Taiwo Adesoye

Dr. Taiwo Adesoye

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2016 in Frontiers in Oncology
Verified
Journal Article
Open access
TATaiwo Adesoye
Taiwo Adesoye
CGCaprice C. Greenberg
Caprice C. Greenberg
HNHeather B. Neuman
Heather B. Neuman
The 2013 Institute of Medicine report investigating cancer care concluded that the cancer care delivery system is in crisis due to an increased demand for care, increasing complexity of treatment, decreasing work force and rising costs. Engaging patients and incorporating evidence-based care into routine clinical practice are essential components of a high quality cancer delivery system. However, a gap currently exists between the identification of beneficial research findings and application in clinical practice. Implementation research strives to address this gap. In this review, we discuss key components of high quality implementation research. We then apply these concepts to a current cancer care delivery challenge in women’s health, specifically the implementation of a surgery decision aid for women newly diagnosed with breast cancer.

24 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
TATaiwo Adesoye
Taiwo Adesoye
DTDebu Tripathy
Debu Tripathy
KHKelly K. Hunt
Kelly K. Hunt
KKKhandan Keyomarsi
Khandan Keyomarsi
Signal Transducer and Activator of Transcription 3 (STAT3) plays a significant role in diverse physiologic processes, including cell proliferation, differentiation, angiogenesis, and survival. STAT3 activation via phosphorylation of tyrosine and serine residues is a complex and tightly regulated process initiated by upstream signaling pathways with ligand binding to receptor and non-receptor-linked kinases. Through downstream deregulation of target genes, aberrations in STAT3 activation are implicated in tumorigenesis, metastasis, and recurrence in multiple cancers. While there have been extensive efforts to develop direct and indirect STAT3 inhibitors using novel drugs as a therapeutic strategy, direct clinical application remains in evolution. In this review, we outline the mechanisms of STAT3 activation, the resulting downstream effects in physiologic and malignant settings, and therapeutic strategies for targeting STAT3. We also summarize the pre-clinical and clinical evidence of novel drug therapies targeting STAT3 and discuss the challenges of establishing their therapeutic efficacy in the current clinical landscape.

1 January 2021 in Journal of Surgical Education
Verified
Journal Article
Closed access
TATaiwo Adesoye
Taiwo Adesoye
CDC.H. Davis
C.H. Davis
HCH. Del Calvo
H. Del Calvo
ASA.F. Shaikh
A.F. Shaikh
VCV. Chegireddy
V. Chegireddy
NTN. Tariq
N. Tariq

24 November 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
TATaiwo Adesoye
Taiwo Adesoye
EDEcaterina E. Dumbrava
Ecaterina E. Dumbrava
KRKanwal P.S. Raghav
Kanwal P.S. Raghav
ASAysegul A. Sahin
Aysegul A. Sahin
HCHui Chen
Hui Chen
FMFunda Meric-Bernstam
Funda Meric-Bernstam
Human epidermal growth factor receptor 2 (HER2) is an established therapeutic target in multiple solid tumors, particularly breast and gastric cancers. Significant advancements have been made in the development of HER2-targeted therapies, including monoclonal antibodies, tyrosine kinase inhibitors, antibody–drug conjugates (ADC), and novel bispecific antibodies. These agents have revolutionized the treatment landscape for HER2-positive metastatic cancers, resulting in improved progression-free and overall survival, and quality of life for patients. Beyond breast and gastric cancers, HER2 expression/amplification has been observed in other solid tumors, such as colorectal, lung, bladder, ovarian, and biliary tract cancers, offering new opportunities for personalized therapy in a larger patient population. In this review, we highlight the current state of HER2-targeted treatment strategies across HER2-expressing solid tumors, discussing the clinical efficacy, adverse event profiles, and challenges of existing therapies. We explore emerging treatment approaches, including novel agents such as HER2-targeting ADCs, combination therapies, and strategies to overcome resistance mechanisms. Additionally, we examine the role of HER2 expression heterogeneity, biomarker-driven patient selection, and diagnostic tools for patient selection and optimization of treatment outcomes. This review also investigates ongoing challenges in expanding HER2-targeted therapies, including addressing intrinsic and acquired resistance and tailoring strategies to low HER2-expressing or HER2-mutant tumors. Lastly, we provide insights into future directions, emphasizing the importance of precision oncology to broaden the therapeutic opportunities of HER2-targeted therapies across diverse HER2-driven malignancies.

28 May 2025 in Cancer
Verified
Journal Article
Open access
KWKerollos Nashat Wanis
Kerollos Nashat Wanis
MMMelissa P. Mitchell
Melissa P. Mitchell
SGSharon H. Giordano
Sharon H. Giordano
JLJennifer Keating Litton
Jennifer Keating Litton
SSSimona F. Shaitelman
Simona F. Shaitelman
TATaiwo Adesoye
Taiwo Adesoye
Background: Selective omission of sentinel lymph node biopsy (SLNB) in patients with early breast cancer limits surgical morbidity. Adoption of this strategy relies on multidisciplinary consensus. Understanding how SLNB omission influences guideline‐based adjuvant treatment decisions, and the proportion of patients impacted, can help guide decision‐making.Patients and methods: Data from the National Cancer Database (2018–2020) was used to estimate the proportions of patients with cT1N0 hormone receptor–positive breast cancer for whom adjuvant chemotherapy, CDK4/6 inhibitor therapy, and regional nodal irradiation decisions would be impacted by the absence of lymph node pathology if national treatment guidelines were followed. Because OncotypeDX score is essential to adjuvant decision‐making when SLNB is omitted, inverse probability weighting was used to estimate the proportions of interest had all individuals undergone OncotypeDX testing.Results: There were 119,312 included patients, with an average age of 63 years, 96,454 (80.8%) having invasive ductal histology, and 52,222 (43.8%) having cT1c tumors. The number of patients with SLNB positivity was 13,211 (11.1%). Among postmenopausal women, 7.9% (95% CI, 7.7–8.1) would have had at least one adjuvant decision impacted by the absence of lymph node pathology. For premenopausal women, the affected proportion was 13.7% (95% CI, 13.0–14.7). When ribociclib decision‐making was not considered, these estimates were 2.5% for postmenopausal women and 12.6% for premenopausal women.Conclusions: SLNB omission has a small – but not negligible – influence on adjuvant decision making in postmenopausal women, whereas a larger proportion of premenopausal women would be impacted. The reported estimates may inform multidisciplinary decision‐making related to SLNB omission.

8 August 2023 in Cancer Medicine
Verified
Journal Article
Open access
TATaiwo Adesoye
Taiwo Adesoye
KLKai‐Ping Liao
Kai‐Ping Liao
SPSusan Peterson
Susan Peterson
LLLiang Li
Liang Li
DZDaria Zorzi
Daria Zorzi
SGSharon H. Giordano
Sharon H. Giordano
Background: Little is known about long‐term treatment‐related symptoms in older breast cancer survivors. We characterized long‐term patient‐reported symptoms and examined factors associated with the presence and severity of symptoms, and symptom interference with daily activities.Methods: Texas Cancer Registry (TCR) Medicare linkage data was used to identify breast cancer patients age 65 and older with local/regional stage disease diagnosed between 2012–2013. Symptom burden was assessed using breast‐specific items from the Patient‐Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO‐CTCAE™). Demographic and clinical data also were collected. Logistic regression models were used to assess the association between symptom burden and respondent sociodemographic and clinical characteristics.Results: Of 4448 eligible patients, 1594 (response‐rate 35.8%) completed questionnaires. Of these, 1245 eligible respondents were included in the analysis based on self‐reported data. Median time from diagnosis to survey completion was 68 months (IQR: 62–73). Most frequently reported symptoms were fatigue/lack of energy (76.8%), aching muscles (72.1%) and aching joints (72.5%). Receipt of chemotherapy was associated with higher symptom burden. Patients treated with adjuvant chemotherapy had higher risk of numbness/tingling (OR: 3.16; 95% CI: 2.36–4.24), hair loss (OR: 2.72; 95% CI: 2.05–3.60), and fatigue/lack of energy (OR: 1.80; 95% CI: 1.29–2.52). Similarly, patients who received chemotherapy were more likely to report the majority of symptoms as moderate to severe and as interfering with daily activities.Conclusion: Receipt of chemotherapy is associated with significant symptom burden more than 5 years after breast cancer treatment. Long‐term chemotherapy impact should be discussed with patients in a shared‐decision making process and approaches to symptom management during survivorship care are needed.